1. Home
  2. VET vs TRVI Comparison

VET vs TRVI Comparison

Compare VET & TRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Vermilion Energy Inc.

VET

Vermilion Energy Inc.

HOLD

Current Price

$8.42

Market Cap

1.4B

Sector

Energy

ML Signal

HOLD

Logo Trevi Therapeutics Inc.

TRVI

Trevi Therapeutics Inc.

HOLD

Current Price

$12.62

Market Cap

1.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
VET
TRVI
Founded
1994
2011
Country
Canada
United States
Employees
N/A
N/A
Industry
Oil & Gas Production
Biotechnology: Pharmaceutical Preparations
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.4B
1.4B
IPO Year
N/A
2019

Fundamental Metrics

Financial Performance
Metric
VET
TRVI
Price
$8.42
$12.62
Analyst Decision
Strong Buy
Analyst Count
0
11
Target Price
N/A
$20.59
AVG Volume (30 Days)
1.4M
2.4M
Earning Date
11-05-2025
11-13-2025
Dividend Yield
4.22%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$1,445,514,003.00
N/A
Revenue This Year
$9.23
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
30.48
N/A
52 Week Low
$5.14
$3.43
52 Week High
$10.49
$14.39

Technical Indicators

Market Signals
Indicator
VET
TRVI
Relative Strength Index (RSI) 44.17 52.54
Support Level $8.54 $12.92
Resistance Level $9.28 $14.39
Average True Range (ATR) 0.36 0.87
MACD -0.10 -0.09
Stochastic Oscillator 10.43 43.71

Price Performance

Historical Comparison
VET
TRVI

About VET Vermilion Energy Inc.

Vermilion Energy Inc is an international oil and gas-producing company. The company engages in full-cycle exploration and production programs that focus on the acquisition, exploration, development, and optimization of producing properties in North America, Europe, and Australia. The majority of Vermilion's revenue is derived from the production and sale of petroleum and natural gas. In each market, the company relies on a host of drilling and well-completion techniques to keep production at attractive levels. Geographically, the company derives majority of its revenue from Canada.

About TRVI Trevi Therapeutics Inc.

Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.

Share on Social Networks: